

**FOR IMMEDIATE RELEASE****Lumiquick Diagnostics Announces Acquisition of AOXRE,  
Expanding Global *In vitro* Diagnostic and Research Capabilities**

**Santa Clara, California, September 8<sup>th</sup>, 2025** – Lumiquick Diagnostics Inc., a U.S.-based leader in the development and manufacturing of *In vitro* diagnostic (IVD) tests, is pleased to announce the acquisition of **AOXRE LLC**, a well-respected research company recognized for its innovative OxisResearch™ product line. At the heart of the OxisResearch™ product line are the Bioxytech™ assay kits targeting oxidative and nitrosative stress biomarkers.

This strategic acquisition marks a significant milestone for Lumiquick Diagnostics as it continues to expand its global footprint and product portfolio in the IVD & Research industries. AOXRE's expertise, technology, and customer relationships will be fully integrated into Lumiquick's operations, strengthening the company's position as a comprehensive provider of high-quality diagnostic and research tools. Dr. Fang Lu, the founder and principal scientist of AOXRE will remain on board to ensure the smooth integration of business.

"We are thrilled to welcome AOXRE into the Lumiquick Diagnostics family," said Charles Yu, President of Lumiquick Diagnostics. "Oxidative stress is associated with damage to biomolecules—including proteins, DNA, and lipids—and has been implicated in numerous diseases such as cardiovascular disorders, diabetes, neurodegenerative conditions (Alzheimer's and Parkinson's), cancer, and chronic infections. The addition of the AOXRE product line will strengthen LumiQuick's ability to support both the clinical and research communities."

With this acquisition, customers can expect:

- **Full product line of oxidative stress markers and companion diagnostic assays**, including Cellular Damage Monitoring, REDOX balance assessment, ELISA, or rapid test of various biological markers that are associated with the oxidation status of the human body.
- **Strong global distribution and customer support**, leveraging Lumiquick's established infrastructure in the United States and both companies' presence in key international markets.
- **Continued dedication to quality, compliance, and innovation**, as both companies share a commitment to advancing research and diagnostic excellence.

AOXRE's existing products and partnerships will remain active during the integration process, ensuring a smooth transition for customers and suppliers. AOXRE's email and website will continue to receive customer inquiries and orders.

This acquisition reflects LumiQuick Diagnostics' long-term growth strategy and dedication to expanding its global impact through strategic partnerships and innovation.

For more information, please contact:

**Talita Franco**

**Business Development Director**

**Email:** [tfranco@lumiquick.com](mailto:tfranco@lumiquick.com)

**Phone:** +1(408) 855-0061

**Website:** [www.lumiquick.com](http://www.lumiquick.com)

---

### **About LumiQuick Diagnostics**

LumiQuick Diagnostics is a U.S.-based manufacturer of high-quality diagnostic test kits, serving customers worldwide. With ISO-certified production facilities and a strong focus on research and innovation, LumiQuick provides solutions in areas such as infectious diseases, fertility, drug abuse testing, and more.

[www.lumiquick.com](http://www.lumiquick.com)

### **About AOXRE**

AOXRE is a respected name in the research industry, known for its innovation, product reliability, and focus on customer needs. The company has served the research community with a broad range of solutions and maintains a strong network of partnerships.

[www.aoxre.com](http://www.aoxre.com)

---